Aplidin in patients with advanced dedifferentiated liposarcomas: a French Sarcoma Group Single-Arm Phase II study

BACKGROUND: Preclinical data have suggested a therapeutic role of JUN pathway activation in dedifferentiated liposarcoma (DDLPS) tumorigenesis. Aplidin(®) is a drug inducing apoptosis through a strong, sustained activation of c-Jun NH2-terminal kinase. METHODS: This phase II trial included patients...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Ann Oncol
Prif Awduron: Toulmonde, M., Le Cesne, A., Piperno-Neumann, S., Penel, N., Chevreau, C., Duffaud, F., Bellera, C., Italiano, A.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Oxford University Press 2015
Pynciau:
Original Articles
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4478976/
https://ncbi.nlm.nih.gov/pubmed/26041763
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdv195
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg